<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368809</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00024484</org_study_id>
    <nct_id>NCT01368809</nct_id>
  </id_info>
  <brief_title>Effect of Fentanyl on Coughing and Recovery After Anesthesia With an LMA Laryngeal Mask Airway)for Airway Management</brief_title>
  <acronym>LMA</acronym>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of Fentanyl on the Incidence of Coughing and Recovery After Propofol-Desflurane Anesthesia With an LMA for Airway Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to evaluate the effectiveness of fentanyl for reducing
      coughing during the perioperative period (i.e., insertion of an LMA [Laryngeal Mask Airway]
      device, maintenance period during surgery, and awakening [emergence] from general anesthesia)
      for ambulatory surgery procedures. Also to assess the effects of fentanyl on the
      postoperative outcomes, (e.g., pain, postoperative nausea and vomiting, return of bowel
      function [constipation], resumption of normal activities of daily living).

      Fentanyl is one of the most common used anesthetic adjuncts for ambulatory surgery because of
      its anesthetic-sparing effects and alleged ability to reduce coughing during instrumentation
      of the patient's airway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is designed to evaluate the effects of fentanyl when administered as an
      adjuvant to standard anesthetic and analgesic drugs on coughing (during insertion of an LMA
      device, during maintenance and emergence from general anesthesia) and on the postoperative
      adverse outcomes (i.e., side effects).

      All patients will receive local anesthetics and commonly used non-opioid pain relieving
      medications during surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Coughing</measure>
    <time_frame>one day</time_frame>
    <description>during the perioperative period (insertion of an LMA device, maintenance of anesthesia, and emergence from general anesthesia) for ambulatory surgery procedures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Nausea and Vomiting</measure>
    <time_frame>1 day</time_frame>
    <description>Postoperative nausea and vomiting using a Verbal Rating Scale (0-10) at PACU (post-anesthesia care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>one day</time_frame>
    <description>Postoperative pain measured using a Verbal Rating Scale (VRS) at post-anesthesia care unit (PACU), (90 minutes after arriving).
Postoperative pain VRS scores: 0 = none pain to 10 = intolerable pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Ambulatory Surgery</condition>
  <condition>Coughing</condition>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Solution 2 ml at induction, 1-2 ml boluses as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>2 ml at induction 1-2 ml boluses as needed</description>
    <arm_group_label>Saline Solution</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients scheduled to undergo outpatient arthroscopic surgery procedures

          -  Willingness and ability to sign an informed consent document

          -  No allergies to anesthetic or analgesic medications

          -  18 - 80 years of age

          -  American Society of Anesthesiologists (ASA) Class I - III adults of either sex

          -  Women of childbearing potential must be currently practicing an acceptable form of
             birth control, and have a negative urine pregnancy test

        Exclusion Criteria

          -  Patients with known allergy, hypersensitivity or contraindications to anesthetic or
             analgesic medications

          -  Patients with clinically-significant medical conditions, such as brain, heart, kidney,
             endocrine, or liver diseases, peptic ulcer disease or bleeding disorders

          -  Pregnant or lactating women

          -  Subjects with a history of alcohol or drug abuse within the past 3 months

          -  Any other conditions or use of any medication which may interfere with the conduct of
             the study (e.g., asthmatic patients history of asthma, chronic cough, or upper
             respiratory tract infection during the previous 2 wk or recent treatment with
             angiotensin-converting enzyme inhibitors, bronchodilators, or steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald H Wender, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <results_first_submitted>September 10, 2015</results_first_submitted>
  <results_first_submitted_qc>September 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2015</results_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Ronald Wender</investigator_full_name>
    <investigator_title>Chairman, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Ambulatory surgery</keyword>
  <keyword>Pain management</keyword>
  <keyword>Perioperative outcomes</keyword>
  <keyword>Fentanyl</keyword>
  <keyword>Coughing during insertion of an LMA</keyword>
  <keyword>Ambulatory surgery procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prior to the day of surgery, potential study patients scheduled to undergo superficial surgical procedures received a packet of materials from their surgeon. The packet contained an initial patient contact letter, a privacy information sheet, and the institution review board (IRB)-approved informed consent form.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fentanyl</title>
          <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
        </group>
        <group group_id="P2">
          <title>Saline Solution</title>
          <description>Saline Solution 2 ml at induction, 1-2 ml boluses as needed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fentanyl</title>
          <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Saline: 2 ml at induction 1-2 ml boluses as needed</description>
        </group>
        <group group_id="B2">
          <title>Saline Solution</title>
          <description>Saline Solution 2 ml at induction, 1-2 ml boluses as needed
Fentanyl: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="14"/>
                    <measurement group_id="B2" value="48" spread="16"/>
                    <measurement group_id="B3" value="48" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Coughing</title>
        <description>during the perioperative period (insertion of an LMA device, maintenance of anesthesia, and emergence from general anesthesia) for ambulatory surgery procedures.</description>
        <time_frame>one day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fentanyl</title>
            <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Saline: 2 ml at induction 1-2 ml boluses as needed</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>Saline Solution 2 ml at induction, 1-2 ml boluses as needed
Fentanyl: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Coughing</title>
          <description>during the perioperative period (insertion of an LMA device, maintenance of anesthesia, and emergence from general anesthesia) for ambulatory surgery procedures.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Nausea and Vomiting</title>
        <description>Postoperative nausea and vomiting using a Verbal Rating Scale (0-10) at PACU (post-anesthesia care unit.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fentanyl</title>
            <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>Saline Solution 2 ml at induction, 1-2 ml boluses as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nausea and Vomiting</title>
          <description>Postoperative nausea and vomiting using a Verbal Rating Scale (0-10) at PACU (post-anesthesia care unit.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Pain</title>
        <description>Postoperative pain measured using a Verbal Rating Scale (VRS) at post-anesthesia care unit (PACU), (90 minutes after arriving).
Postoperative pain VRS scores: 0 = none pain to 10 = intolerable pain.</description>
        <time_frame>one day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fentanyl</title>
            <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
          </group>
          <group group_id="O2">
            <title>Saline Solution</title>
            <description>Saline Solution 2 ml at induction, 1-2 ml boluses as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Pain</title>
          <description>Postoperative pain measured using a Verbal Rating Scale (VRS) at post-anesthesia care unit (PACU), (90 minutes after arriving).
Postoperative pain VRS scores: 0 = none pain to 10 = intolerable pain.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.8"/>
                    <measurement group_id="O2" value="1.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No adverse event reported during the study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fentanyl</title>
          <description>Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
Saline: 2 ml at induction 1-2 ml boluses as needed</description>
        </group>
        <group group_id="E2">
          <title>Saline Solution</title>
          <description>Saline Solution 2 ml at induction, 1-2 ml boluses as needed
Fentanyl: Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul F White</name_or_title>
      <organization>Department of Anesthesiology at Cedars-Sinai Medical Center in Los Angeles</organization>
      <phone>214-7703775</phone>
      <email>paul.white@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

